CD14 and adult-onset Still disease: Compared with HC subjects, active AOSD patients had significantly higher LPO levels on erastin-treated CD14+ cells (median fold, 1.71, IQR 1.19–3.10 versus 0.97, IQR 0.84–1.07, p < 0.05) (Figure 3A), but this was not observed on erastin-treated PBMCs (Figure 3B).